Maven Securities’s ClearPoint Neuro CLPT Stock Holding History

Maven Securities’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,507	Closed	-$32K	–	1096
2021 Q1	$32K	Buy	+1,507	New	+$32.3K	﹤0.01%	1119

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TFCM

Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CCM

Conway Capital Management Burbank, California $214M AUM 22.99% 1-Year Est. Return

Maven Securities's CLPT Position: Q2 2021 in Review

Maven Securities sold out of ClearPoint Neuro (CLPT) in Q2 2021, closing a stake of 1,507 shares — an estimated $32K sold.

Maven Securities first reported a position in CLPT in Q1 2021 and held it in 1 quarter. The position peaked at $32K in Q1 2021. 76 funds tracked by Wall St. Rank hold CLPT as of Q2 2021.

Maven Securities reported no remaining ClearPoint Neuro position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 1,507 ClearPoint Neuro shares in Q2 2021, an estimated $32K.
Maven Securities first reported a position in ClearPoint Neuro in Q1 2021 and held it in 1 quarter.
Maven Securities's ClearPoint Neuro position peaked at $32K in Q1 2021.
76 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.